EGFR and head and neck squamous cell carcinoma: Furthermore, the use of cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), in combination with cisplatin or carboplatin and 5-fluorouracil (5FU) as a first-line treatment of recurrent/metastatic (R/M) HNSCC (EXTREME) has some utility with improved overall survival compared to platinum plus 5FU treatment with a response rate in about one third of patients [26].